Pharmacokinetic Study of Porfiromycin in Head and Neck Cancer and Other Cancer Patients With Solid Tumors

Inclusion Criteria:

* Patients with histologically proven advanced head and neck cancer or other solid tumors undergoing radiation therapy
* Patients with prior chemotherapy will be considered if chemotherapy occurred more than 30 days prior to this study
* Patients must be receiving concomitant radiotherapy (RT)
* Performance status of ≥ 70% on the Karnofsky performance scale (KPS)
* Must be ≥ 18 years of age
* Expected survival of at least three months
* Written informed consent

Exclusion Criteria:

* Patients who meet any of the following clinical laboratory criteria:

  * Granulocyte count of \< 2000/mm\*\*3
  * Platelets \< 75,000/mm\*\*3
  * Serum creatinine \> 1.5 times the upper limit of normal
  * Bilirubin \> 1.5 times the upper limit of normal
  * Prothrombin time and partial thromboplastin time \> 1.5 times the upper limit of normal
* Women who are pregnant
* Men and women of child-bearing potential who are unwilling to utilize a medically acceptable method of contraception
* Patients who have any known bleeding disorder at the discretion of the investigator
* Presence of any other life-threatening illness, such as unstable angina, severe oxygen dependent chronic obstructive pulmonary disease, or unstable liver or renal disease
* Treatment with granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor or Interleukin-1l within 30 days prior to the start of RT
* Patients who have had prior exposure to mitomycin C or porfiromycin